Colchicine and Cardiovascular Diseases

Dasgeb B, Kornreich D, McGuinn K, et al., Colchicine: an ancient drug with novel applications. British Journal of Dermatology. 2018 Feb 1;178(2):350-6, doi:10.1111/bjd.15896

Bhattacharyya B, Panda D, Gupta S, et al., Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Medicinal Research Reviews 2008;28:155–83,doi: 10.1002/med.20097

Terkeltaub RA. Colchicine update: 2008. Seminars in Arthritis Rheumatism. 2009;38:411–9 doi:10.1016/j.semarthrit.2008.08.006

Slobodnick, A.; Shah, B.; Pillinger, M.H., et al., Colchicine: Old and New. American Journal of Medicine. 2014, 128, 461–470, doi:10.1016/j.amjmed.2014.12.010

P.C. Robinson, R. Terkeltaub, M.H. Pillinger, et al., Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease, American Journal of Medicine 135 (2022) 32–38, doi:10.1016/j. amjmed.2021.07.025.

Leung, Y.Y.; Yao Hui, L.L.; Kraus, V.B. Colchicine-Update on mechanisms of action and therapeutic uses. Seminars in Arthritis Rheumatism. 2015, 45, 341–350, doi:10.1016/j.semarthrit.2015.06.013

Angelidis, C.; Kotsialou, Z.; Kossyvakis, et al., Colchicine Pharmacokinetics and Mechanism of Action. Current Pharmaceutical Design. 2018, 24, 659–663, doi:10.2174/1381612824666180123110042

Hung IF, Wu AK, Cheng VC, et al., Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clinical Infectious Diseases. 2005 Aug 1;41(3):291-300, doi: 10.1086/431592.

Caner JE. Colchicine inhibition of chemotaxis. Arthritis & Rheumatism. 1965;8:757– 764. doi: 10.1002/art.1780080438

Cronstein BN, Molad Y, Reibman J, et al., Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. Journal of Clinical Investigation. 1995;96:994–1002. doi: 10.1172/JCI118147

Ding AH, Porteu F, Sanchez E, et al., Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents. Journal of Experimental Medicine. 1990;171:715–727. doi: 10.1084/jem.171.3.715

Li Z, Davis GS, Mohr C, et al., Inhibition of LPS-induced tumor necrosis factor-alpha production by colchicine and other microtubule disrupting drugs. Immunobiology. 1996;195:624–639. doi: 10.1016/ s0171-2985(96)80027-1

Roberge CJ, Gaudry M, de Médicis R, et al., Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. Journal of Clinical Investigation. 1993;92:1722–1729. doi: 10.1172/JCI116759

Wright DG, Malawista SE. Mobilization and extracellular release of granular enzymes from human leukocytes during phagocytosis: inhibition by colchicine and cortisol but not by salicylate. Arthritis & Rheumatism. 1973;16:749–758. doi: 10.1002/art.1780160608

Martinon F, Pétrilli V, Mayor A, et al., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237– 241. doi: 10.1038/nature04516

Park YH, Wood G, Kastner DL, et al., Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nature Immunology. 2016;17:914–921. doi: 10.1038/ni.3457

Mastrocola R, Penna C, Tullio F, et al., Pharmacological inhibition of NLRP3 inflammasome attenuates myocardial ischemia/reperfusion injury by activation of RISK and mitochondrial pathways. Oxidative Medicine and Cellular Longevity. 2016;2016:5271251. doi: 10.1155/2016/5271251

Kirii H, Niwa T, Yamada Y, et al., Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology,. 2003;23:656– 660. doi: 10.1161/01.ATV.0000064374.15232.C3

Mallat Z, Corbaz A, Scoazec A, et al., Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001;104:1598–1603. doi: 10.1161/hc3901.096721

Garlanda C, Dinarello CA, Mantovani A. , The interleukin-1 family: back to the future. Immunity. 2013;39:1003–1018. doi: 10.1016/j.immuni.2013.11.010

Bauriedel G, Heimerl J, Beinert T, et al., Colchicine antagonizes the activity of human smooth muscle cells cultivated from arteriosclerotic lesions after atherectomy. Coronary Artery Disease. 1994;5:531–539. PMID: 7952413

Weng, JH., Koch, P.D., Luan, H.H. et al., Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation. Nature Metabolism 3, 513–522 (2021). doi:10.1038/s42255-021-00366-y

Terkeltaub RA, Furst DE, Bennett K, et al., High versus low dosing of oral colchicine for early acute gout flare: Twenty-fourhour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis & Rheumatism. 2010;62:1060–1068. doi: 10.1002/art.27327

P.C. Robinson, R. Terkeltaub, M.H. Pillinger, et al., Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease, American Journal of Medicine 135 (2022) 32–38, doi:10.1016/j. amjmed.2021.07.025.

Andreis A, Imazio M, Avondo. Adverse events of colchicine for cardiovascul, et al.,ar diseases: a comprehensive meta-analysis of 14188 patients from 21 randomized controlled trials. Journal of Cardiovascular Medicine (Hagerstown). 2021;22:637–644. doi: 10.2459/JCM.0000000000001157

Stewart S, Yang KCK, Atkins K, et.al., Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Research & Therapy. 2020;22:28, doi: 10.1186/ s13075-020-2120-7

Hemkens LG, Ewald H, Gloy VL, et al. Colchicine for prevention of cardiovascular events. Cochrane Database Systematic Reviews 2016; 2016: CD011047. doi: 10.1002/14651858.CD011047.pub2.

Imazio M, Brucato A, Maestroni S, et.al, Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123:1092–1097, doi: 10.1161/CIRCULATIONAHA.110.986372

Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112:2012–2016. doi: 10.1161/CIRCULATIONAHA.105.542738

Imazio M, Brucato A, Cemin R, et al; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. New England Journal of Medicine. 2013;369:1522–1528. doi: 10.1056/NEJMoa1208536

Sambola A, Roca Luque I, Mercé J, et al., Colchicine administered in the first episode of acute idiopathic pericarditis: a randomized multicenter open-label study. Revista Espanola Cardiologia (English Edition). 2019;72:709–716. doi: 10.1016/j.rec.2018.11.016

Imazio M, Bobbio M, Cecchi E, et al., Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Archives of Internal Medicine. 2005;165:1987–1991. doi: 10.1001/archinte.165.17.1987

Imazio M, Bobbio M, Cecchi E, et al., Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Archives of Internal Medicine. 2005;165:1987–1991. doi: 10.1001/archinte.165.17.1987

Imazio M, Brucato A, Cemin R, et al., CORP Investigators. Colchicine for recurrent pericarditis (CORP): a randomized trial. Annals of Internal Medicine 2011;155:409–414. doi: 10.7326/0003- 4819-155-7-201110040-00359

Adler Y, Charron P, Imazio M, et al., ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36:2921- 2964. doi: 10.1093/eurheartj/ehv318

O’Gara PT, Kushner FG, Ascheim DD, et al., ACC Foundation/AHA Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the ACC/AHA Task Force on Practice Guidelines. Circulation. 2013;127:e362–e425. doi: 10.1161/CIR.0b013e3182742cf6

Imazio M, Brucato A, Ferrazzi P, et al., Postpericardiotomy syndrome: a proposal for diagnostic criteria. Journal of Cardiovascular Medicine, 2013;14:351–353. doi:10.2459/JCM.0b013e328353807d

Finkelstein Y, Shemesh J, Mahlab K, et al., Colchicine for the prevention of postpericardiotomy syndrome. Herz. 2002;27:791–794. doi: 10.1007/s00059-002-2376-5

Imazio M, Trinchero R, Brucato A, et al., COPPS Investigators. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. European Heart Journal. 2010;31:2749–2754. doi: 10.1093/eurheartj/ehq319

Imazio M, Brucato A, Ferrazzi P, et al., COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312:1016–1023. doi: 10.1001/jama.2014.11026

Meurin P, Lelay-Kubas S, Pierre B, et al., French Society of Cardiology. Colchicine for postoperative pericardial effusion: a multicentre, doubleblind, randomised controlled trial. Heart. 2015;101:1711–1716. doi: 10.1136/heartjnl-2015-307827

Deftereos SG, Beerkens FJ, Shah B et al., Colchicine in Cardiovascular Disease: In-Depth Review. Circulation. 2022 Jan 4;145(1):61-78. doi: 10.1161/CIRCULATIONAHA.121.056171.

Nidorf M, Thompson P, et al. Effect of colchicine (0.5mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. American Journal of Cardiology. 2007;99:805–807. doi: 10.1016/j.amjcard.2006.10.039

Vaidya K, Arnott C, Martínez GJ, Ng B, et al., Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. JACC Cardiovascular Imaging. 2018 Feb;11(2 Pt 2):305-316. doi: 10.1016/j.jcmg.2017.08.013.

Cox P, Gupta S, Zhao SS, et al., The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis. Rheumatology International. 2021 Jul;41(7):1209-1219. doi: 10.1007/s00296-021-04876-6.

Shah B, Toprover M, Crittenden DB, et al., Colchicine Use and Incident Coronary Artery Disease in Male Patients With Gout. Canadian Journal of Cardiology. 2020 Nov;36(11):1722-1728. doi: 10.1016/j.cjca.2020.05.026

Ridker P. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. European Heart Journal 2016 Jun 7;37(22):1720-2. doi: 10.1093/eurheartj/ehw024.

Ridker PM, Bhatt DL, Pradhan AD, et al., PROMINENT, REDUCE-IT, and STRENGTH Investigators. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023 Apr 15;401(10384):1293-1301. doi: 10.1016/S0140-6736(23)00215-5.

Nidorf S, Fiolet A, Mosterd A, et al., Colchicine in patients with chronic coronary disease. New England Journal of Medicine. 2020;383:1838–1847. doi: 10.1056/NEJMoa2021372

Opstal T, Nidorf S, Fiolet A, et al., Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial. International Journal of Cardiology. 2023;372:1–5. doi: 10.1016/j.ijcard.2022.12.026

Tardif JC, Kouz S, Waters DD, et al., Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388.

Deftereos S, Giannopoulos G, Angelidis C, et al., Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation 2015;132:1395–1403. doi: 10.1161/CIRCULATIONAHA.115.017611

Hennessy T, Soh L, Bowman M, et al., The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. American Heart Journal. 2019;215:62–69. doi: 10.1016/j.ahj.2019.06.003

Tong DC, Quinn S, Nasis A, et al., Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020 Nov 17;142(20):1890-1900. doi: 10.1161/CIRCULATIONAHA.120.050771.

Akrami M, Izadpanah P, Bazrafshan M et al., Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. BMC Cardiovascular Disorder. 2021 Dec 7;21(1):583. doi: 10.1186/s12872-021-02393-9.

Mewton N, Roubille F, Bresson D, et al., Effect of colchicine on myocardial injury in acute myocardial infarction. Circulation. 2021;144:859–869. doi: 10.1161/CIRCULATIONAHA.121.056177

Shah B, Pillinger M, Zhong H, et al., Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial. Circulation Cardiovascular Interventions. 2020;13:e008717, doi: 10.1161/CIRCINTERVENTIONS.119.008717

Cole J, Htun N, Lew R, et al., Colchicine to prevent periprocedural myocardial injury in percutaneous coronary intervention: the COPE-PCI pilot trial. Circulation Cardiovascular Interventions. 2021;14:e009992, doi: 10.1161/CIRCINTERVENTIONS.120.009992

Lawler PR, Bhatt DL, Godoy LC, et al., M. Targeting cardiovascular inflammation: next steps in clinical translation. European Heart Journal. 2021;42:113–131. doi: 10.1093/eurheartj/ehaa099

Almagor M, Keren A, Banai S. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. American Heart Journal. 2003;145:248–253. doi: 10.1067/mhj.2003.16

O’Keefe JH Jr, McCallister BD, Bateman TM, et al., Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. Journal of American College of Cardiology. 1992;19:1597–1600, doi: 10.1016/0735-1097(92)90624-v

Freed M, Safian RD, O’Neill WW, et al., Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty. American Journal of Cardiology. 1995;76:1185–1188,vdoi: 10.1016/s0002-9149(99)80334-8

Rodríguez-Granillo AM, Correa-Sadouet C, Gallardo C, et al., ORCA investigators. Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention. Circulation. 2022;146:A9859. https://doi.org/10.1161/circ.146.suppl_1.9859

Preau S, Montaigne D, Modine T, et al., Macrophage migration inhibitory factor induces contractile and mitochondria dysfunction by altering cytoskeleton network in the human heart. Critical Care Medicine 2013; 41:e125–33, doi: 10.1097/CCM.0b013e31827c0d8c

Kerfant BG, Vassort G, Gómez AM. Microtubule disruption by colchicine reversibly enhances calcium signaling in intact rat cardiac myocytes. Circulation Research 2001;88(7):E59-E65. doi: 10.1161/hh0701.090462

Gómez AM, Kerfant BG, Vassort G, et al., Autonomic regulation of calcium and potassium channels is oppositely modulated by microtubules in cardiac myocytes. American Journal of Physiology Heart and Circulation Physiology 2004;286:H2065-H2071. doi:10.1152/ajpheart.00933.2003

Imazio M, Brucato A, Ferrazzi P, et al., Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation 2011;124:2290-5. doi:10.1161/CIRCULATIONAHA.111.026153

January CT, Wann LS, Alpert JS, et al., ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the ACC/AHA Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199–e267. doi: 10.1161/CIR.0000000000000041

Agarwal S, Beard CW, Khosla J, et al., Safety and efficacy of colchicine for the prevention of post-operative atrial fibrillation in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Europace. 2023; Jul 4;25(7):euad169. doi: 10.1093/europace/euad169.

Conen D, Ke Wang M, Popova E,et al., Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. Lancet. 2023 Aug 25:S0140-6736(23)01689-6. doi: 10.1016/S0140-6736(23)01689-6.

Lim HS, Schultz C, Dang J, et al., Time course of inflammation, myocardial injury, and prothrombotic response after radiofrequency catheter ablation for atrial fibrillation. Circulation Arrhythmia and Electrophysiology. 2014 Feb;7(1):83-9. doi: 10.1161/CIRCEP.113.000876

Deftereos S, Giannopoulos G, Efremidis M, et al., Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life. Heart Rhythm. 2014;11:620–628. doi: 10.1016/j.hrthm.2014.02.002

Ahmed AS, Miller J, Foreman J, et al., Prophylactic Colchicine After Radiofrequency Ablation of Atrial Fibrillation: The PAPERS Study. Journal of the American College of Cardiology Clinical Electrophysiology. 2023 Jul;9(7 Pt 2):1060-1066. doi: 10.1016/j.jacep.2023.02.003

Calkins H, Hindricks G, Cappato R et al., 2017HRS/EHRA/ECAS/APHRS/ SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace. 2018;20:157–208. doi: 10.1093/europace/eux275

Murphy SP, Kakkar R, McCarthy CP, Januzzi JL. Inflammation in Heart Failure. Journal of American College of Cardiology. 2020 Mar 24;75(11):1324-1340. doi: 10.1016/j.jacc.2020.01.014.

Garofalo M, Corso R, Tomasoni D et al., Inflammation in acute heart failure. Frontiers in Cardiovascular Medicine. 2023 Nov 17;10:1235178. doi: 10.3389/fcvm.2023.1235178.

Deftereos S, Giannopoulos G, Panagopoulou V, et al., Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. Journal of American College of Cardiology Heart Failure. 2014 Apr;2(2):131-7. doi: 10.1016/j.jchf.2013.11.006.

Roth ME, Chinn ME, Dunn SP, Bilchick K C. Association of colchicine use for acute gout with clinical outcomes in decompansated heart failure. Clinical Cardiology 2022;45:733-741. doi:10.1002/clc.23830

Pascual-Figal D, Núñez J, Pérez-Martínez MT et al., Colchicine in acutely decompensated heart failure: the COLICA trial. European Heart Journal. 2024 Aug 30:ehae538. doi: 10.1093/eurheartj/ehae538.

Buckley LF, Dorbala P, Claggett BL, et al., Circulating neutrophil-related proteins associate with incident heart failure and cardiac dysfunction: The ARIC study. European Journal of Heart Failure. 2023 Nov;25(11):1923-1932. doi: 10.1002/ejhf.3008

Imazio M, Trinchero R. Myopericarditis: Etiology, management, and prognosis. International Journal of Cardiology. 2008 Jun 23;127(1):17-26. doi: 10.1016/j.ijcard.2007.10.053.

Collini V, De Martino M, Andreis A et al., Efficacy and safety of colchicine for the treatment of myopericarditis. Heart. 2024 Apr 25;110(10):735-739. doi: 10.1136/heartjnl-2023-323484.

Attar R, Wester A, Koul S et al., Peripheral artery disease and outcomes in patients with acute myocardial infarction. Open Heart. 2019 May 12;6(1):e001004. doi: 10.1136/openhrt-2018-001004.

Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006 Aug 15;114(7):688-99. doi: 10.1161/CIRCULATIONAHA.105.593442.